Pharmaceuticals 2010, 3(3), 448-470; doi:10.3390/ph3030448

Cell-Penetrating Peptides for Antiviral Drug Development

School of Public Health, University of California, Berkeley, CA 94720, USA
* Author to whom correspondence should be addressed.
Received: 24 December 2009; in revised form: 6 February 2010 / Accepted: 1 March 2010 / Published: 2 March 2010
(This article belongs to the Special Issue Cell-penetrating Peptides)
PDF Full-text Download PDF Full-Text [525 KB, uploaded 2 March 2010 14:41 CET]
Abstract: Viral diseases affect hundreds of millions of people worldwide, and the few available drugs to treat these diseases often come with limitations. The key obstacle to the development of new antiviral agents is their delivery into infected cells in vivo. Cell-penetrating peptides (CPPs) are short peptides that can cross the cellular lipid bilayer with the remarkable capability to shuttle conjugated cargoes into cells. CPPs have been successfully utilized to enhance the cellular uptake and intracellular trafficking of antiviral molecules, and thereby increase the inhibitory activity of potential antiviral proteins and oligonucleotide analogues, both in cultured cells and in animal models. This review will address the notable findings of these studies, highlighting some promising results and discussing the challenges CPP technology has to overcome for further clinical applications.
Keywords: cell-penetrating peptide; antivirals; antisense; drug delivery

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Delcroix, M.; Riley, L.W. Cell-Penetrating Peptides for Antiviral Drug Development. Pharmaceuticals 2010, 3, 448-470.

AMA Style

Delcroix M, Riley LW. Cell-Penetrating Peptides for Antiviral Drug Development. Pharmaceuticals. 2010; 3(3):448-470.

Chicago/Turabian Style

Delcroix, Melaine; Riley, Lee W. 2010. "Cell-Penetrating Peptides for Antiviral Drug Development." Pharmaceuticals 3, no. 3: 448-470.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert